ClinicalTrials.gg
RecruitingNCT06980272Updated Jun 24, 2025

SSGJ-707 in Advanced Non-Small Cell Lung Cancer

A Phase 3 interventional study of SSGJ-707 and Pembrolizumab in Advanced Non-Small Cell Lung Cancer, sponsored by Shenyang Sunshine Pharmaceutical Co., LTD.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-24.

Sponsored by Shenyang Sunshine Pharmaceutical Co., LTD. (part of 3SBio Inc.) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Jun 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
420
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,880 studies in Carcinoma, Non-Small-Cell Lung with a site in China — 763 open to participants now, 987 under way, 203 of them phase 3. Carcinoma, Non-Small-Cell Lung · China.

Planned enrollment
266th of 1,593
420 · median 100
Started
2025
with 207 others
Phase 3
366 of 1,880
105 open now
Primary completion
2026-07
later than 369 of 986 live
Registered
1,551st of 1,880
by date

Among the 1,880 studies in Carcinoma, Non-Small-Cell Lung with a site in China, this one is the 266th largest by planned enrollment of the 1,593 interventional ones that give a count, is one of 208 that started in 2025, is one of 366 in phase 3, reaches primary completion later than 369 of the 986 other live ones, and was the 1,551st registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

763 of the 1,880 studies in Carcinoma, Non-Small-Cell Lung with a site in China are open now. Recruiting first, the newest first:

758 more — sign in →

All 763 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,880 studies in Carcinoma, Non-Small-Cell Lung with a site in China, or all of them as a file.
02

Study summary

This trial is a Phase III study. All patients are stage IIIB/C (unsuitable for radical therapy) or IV non-small cell lung cancer(NSCLC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1. The purpose of this study is to evaluate the efficacy and safety of SSGJ-707 comparing Pembrolizumab in subjects with advanced NSCLC whose tumors have a programmed cell death-ligand 1 (PD-L1) Tumor Proportion Score (TPS) greater than or equal to 1%.

03

Conditions studied

  • Advanced Non-Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willing to participate in the study voluntarily, agree to comply with and complete all study procedures, and sign the Form (ICF).
  2. At least 18 years of age at the time of signing the ICF, regardless of gender.
  3. (ECOG) Performance Status (PS) of 0 or 1.
  4. of at least 12 weeks.
  5. or cytologically confirmed locally advanced (Stage IIIB/IIIC) or (Stage IV) non-small cell lung cancer (NSCLC).
  6. No prior systemic anti-tumor treatment for locally advanced or metastatic NSCLC.
  7. At least one measurable tumor lesion as a target lesion according to v1.1 criteria.

Exclusion criteria

Exclusion Criteria:

  1. Presence of small cell carcinoma components in histological pathology.
  2. Presence of EGFR-sensitive mutations or ALK fusion-positive NSCLC.
  3. Known BRAF V600E mutation, MET exon 14 skipping mutation, NTRK fusion, RET fusion, or ROS1 fusion-positive NSCLC.
  4. Presence of brainstem, , spinal cord or compression.
  5. Unresolved toxicity from prior anti-tumor treatment, defined as toxicity not returning to Version 5.0 Grade 0 or 1.
  6. History of allogeneic organ transplantation and hematopoietic stem cell transplantation.
  7. History of immunodeficiency; positive for antibodies;
  8. Known active tuberculosis (TB);
  9. Known history of severe allergy to any component of the drug, or history of severe allergic reactions to chimeric or humanized antibodies.
  10. Pregnant or breastfeeding women.

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
420 participants (estimated)

Study arms

  • Experimental
    SSGJ-707

    Subjects receive SSGJ-707 monotherapy intravenously (IV), selected dose.

    Drug: SSGJ-707

  • Active comparator
    Pembrolizumab

    Subjects receive Pembrolizumab monotherapy intravenously (IV), 200mg q3w.

    Drug: Pembrolizumab

Interventions

  • Subjects receive SSGJ-707 intravenously.

  • Subjects receive Pembrolizumab intravenously.

06

What researchers measure

Primary outcomes

  1. PFS assessed by IRRC per RECIST v1.1

    Progression-free survival (PFS) is defined as the time from the date of randomization till the first documentation of disease progression (per RECIST v1.1 criteria) assessed by the blinded IRRC or death due to any cause (whichever occurs first).

    Time frame: Up to 2 approximately years

Secondary outcomes

  1. OS

    Overall Survival (OS) is defined as the time from the start of treatment with SSGJ-707 until death due to any cause.

    Time frame: Up to 2 approximately years

  2. ORR assessed by IRRC per RECIST v1.1

    ORR is the proportion of subjects with complete response(CR) or partial response(PR) , based on RECIST v1.1.

    Time frame: Up to 2 approximately years

  3. DoR assessed by IRRC per RECIST v1.1

    Duration of response (DoR) assessed according to RECIST v1.1.

    Time frame: Up to 2 approximately years

  4. DCR assessed by IRRC per RECIST v1.1

    Disease control rate (DCR) assessed according to RECIST v1.1.

    Time frame: Up to 2 approximately years

  5. TTR assessed by IRRC per RECIST v1.1

    Time to response (TTR) is defined as the time to response base on RECIST v1.1.

    Time frame: Up to 2 approximately years

  6. PFS assessed by investigator per RECIST v1.1

    Progression-free survival (PFS) is defined as the time from the date of randomization till the first documentation of disease progression assessed by the investigator or death due to any cause (whichever occurs first).

    Time frame: Up to 2 approximately years

  7. ORR assessed by the investigator per RECIST v1.1

    ORR is the proportion of subjects with complete response(CR) or partial response(PR) , based on RECIST v1.1.

    Time frame: Up to 2 approximately years

  8. DoR assessed by the investigator per RECIST v1.1

    Duration of response (DoR) assessed according to RECIST v1.1.

    Time frame: Up to 2 approximately years

  9. DCR assessed by the investigator per RECIST v1.1

    Disease control rate (DCR) assessed according to RECIST v1.1.

    Time frame: Up to 2 approximately years

  10. TTR assessed by the investigator per RECIST v1.1

    Time to response (TTR) is defined as the time to response base on RECIST v1.1.

    Time frame: Up to 2 approximately years

  11. AE

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment.

    Time frame: Up to 2 approximately years

  12. ADA

    Number of subjects with detectable anti-drug antibodies (ADA).

    Time frame: Up to 2 approximately years

  13. PD-L1 expression

    The correlationship between PD-L1 expression and SSGJ-707 anti-tumor activity.

    Time frame: Up to 2 approximately years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jul 2026, 13 months after the start.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's planned 13 months is below that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2025
First posted
May 20, 2025
StartActual
Jun 20, 2025
Primary completionEst.
Jul 30, 2026
CompletionEst.
Dec 31, 2028
Last update
Jun 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06980272
Responsible party
Sponsor
First posted
May 20, 2025
Start date
Jun 20, 2025
Primary completion
Jul 30, 2026 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Jun 24, 2025

Study contacts

Caicun Zhou
Contact
caicunzhoudr@tongji.edu.cn
13301825532

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-PD-1/Anti-VEGF Bispecific Antibody PF-08634404

Start the discussion